AbCellera's success is unprecedented: what have we learned?. Issue 12 (7th June 2021)

• Record Type: Journal Article
• Authors: Sinton, David; Kelley, Shana O.
• Is Part Of: Lab on a chip. Volume 21:Issue 12(2021)
• Page Start: 2330
• Page End: 2332
• Publication Date: 2021-06-07
• Subjects: Miniature electronic equipment -- Periodicals; Combinatorial chemistry -- Periodicals; Biotechnology -- Periodicals; 543.0813
• DOI: 10.1039/d1lc00155h
• Languages: English
• ISSNs: 1473-0197

Abstract

Abstract : The search for antibody therapeudic candidates is a timely and important challenge well-suited to lab on a chip approaches. Abstract : The search for antibody therapeutic candidates is a timely and important challenge well-suited to lab on a chip approaches. Vancouver-based AbCellera Biologics Inc. developed a microfluidic antibody screening platform, ancillary technologies, and a service-based drug discovery business model that has proved a tremendous success. We take the opportunity here to reflect on what enabled this success. We consider the common lab on a chip motivations that were part of their success, and those that were not.